Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical currently has an Earnings ESP of ... Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success.

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...

Globus Medical, Inc. (NYSE:GMED – Free Report) – Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued ...

Before you invest in Globus Medical, Inc. (GMED), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth. Montgomery County's Globus Medical has agreed to acquire a California life ...